Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesalamine 4g ER granules for induction of remission in mild to moderate UC
NCT02522767Phase 3Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Oct 2015
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of Salcrozine in ulcerative colitis (UC), sponsored by Ferring Pharmaceuticals. Started Oct 2015; status: completed.
02
Drugs
Salcrozine
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02522767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02522767.